Kiersten Ricci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kiersten Ricci has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Adrienne Marie Hammill
Division of Hematology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA
6 shared publications Elissa Engel
Department of Pediatrics University of Cincinnati College of Medicine Cincinnati Ohio USA
4 shared publicationsManish Patel
Cincinnati Children's Hospital Medical Center
3 shared publications- Michael Jeng
Division of Pediatric Hematology Oncology Lucile Packard Children's Hospital Stanford University School of Medicine Stanford California USA
3 shared publications Roshni Dasgupta
Cincinnati Children's Hospital Medical Center
3 shared publications- Thomas Williams McLean
Section of Hematology/Oncology Department of Pediatrics Wake Forest University School of Medicine Winston‐Salem North Carolina USA
3 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (7) , e70335
Outcomes of Live Virus Vaccination in Patients With Vascular Anomalies Being Treated With Sirolimus
Background: Live vaccination in patients with vascular anomalies (VA) receiving sirolimus remains controversial due to immunosuppressive effects and theoretical risks. Procedure: This single‐center retrospective study included patients with VA less than 4 years old at the start of sirolimus therapy who were incompletely vaccinated. Immunologic evaluation during sirolimus therapy was categorized as normal, abnormal, or no/partial evaluation. Based on results, patients were encouraged to proceed with live attenuated vaccinations (varicella zoster virus [VZV]; measles–mumps–rubella [MMR]) or discussed with immunology. Vaccination outcomes were reviewed and reported descriptively. Results: Among 45 eligible patients, 24 (53%) underwent complete immunologic evaluation. Thirteen of these (54%) had normal results; five of these (38%) were vaccinated while on sirolimus without complication. Eleven (46%) had abnormal evaluations; four of these (36%) were vaccinated while on sirolimus, with one developing a self‐limiting varicella‐like rash and fever. Twenty‐one patients (47%) had partial or no immunological evaluation; 10 of these (48%) proceeded with vaccination while on sirolimus without complications. Overall, 24 patients (53%) received live vaccines (19 on sirolimus, five after holding sirolimus therapy for at least 2 months), with only one experiencing a mild vaccine‐related event. No life‐threatening complications occurred. Conclusion: In young patients with VA receiving sirolimus, live vaccine‐associated infection risk appears low and comparable to rates in solid organ transplant recipients on immunosuppression. Immunologic evaluation may help identify those at higher risk, though most tolerated vaccination without adverse events. Our practice prioritizes varicella vaccination first, given the availability of effective treatment for potential complications.
- 21 April 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (7) , e70335
Open AccessOutcomes of Live Virus Vaccination in Patients With Vascular Anomalies Being Treated With Sirolimus
Background: Live vaccination in patients with vascular anomalies (VA) receiving sirolimus remains controversial due to immunosuppressive effects and theoretical risks. Procedure: This single‐center retrospective study included patients with VA less than 4 years old at the start of sirolimus therapy who were incompletely vaccinated. Immunologic evaluation during sirolimus therapy was categorized as normal, abnormal, or no/partial evaluation. Based on results, patients were encouraged to proceed with live attenuated vaccinations (varicella zoster virus [VZV]; measles–mumps–rubella [MMR]) or discussed with immunology. Vaccination outcomes were reviewed and reported descriptively. Results: Among 45 eligible patients, 24 (53%) underwent complete immunologic evaluation. Thirteen of these (54%) had normal results; five of these (38%) were vaccinated while on sirolimus without complication. Eleven (46%) had abnormal evaluations; four of these (36%) were vaccinated while on sirolimus, with one developing a self‐limiting varicella‐like rash and fever. Twenty‐one patients (47%) had partial or no immunological evaluation; 10 of these (48%) proceeded with vaccination while on sirolimus without complications. Overall, 24 patients (53%) received live vaccines (19 on sirolimus, five after holding sirolimus therapy for at least 2 months), with only one experiencing a mild vaccine‐related event. No life‐threatening complications occurred. Conclusion: In young patients with VA receiving sirolimus, live vaccine‐associated infection risk appears low and comparable to rates in solid organ transplant recipients on immunosuppression. Immunologic evaluation may help identify those at higher risk, though most tolerated vaccination without adverse events. Our practice prioritizes varicella vaccination first, given the availability of effective treatment for potential complications.
- 17 March 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (6) , e31661
Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States
Patients with vascular anomalies (VAs) require expert multidisciplinary care. No prior studies have characterized the sociodemographic characteristics across multiple VA centers. We collected data on 5783 patients receiving care at 20 VA centers between July 1, 2020 through December 31, 2022. Male patients were underrepresented compared to the state‐level census data at 17/20 centers. Black and Asian patients were underrepresented at 14/20 and 12/20 centers, respectively. The median distance to the hospital was 48 miles, and median age was 12.0 years. These data suggest that race, sex, age, and distance from the hospital could impede the ability to access expert VA care.
- 17 March 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (6) , e31661
Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States
Patients with vascular anomalies (VAs) require expert multidisciplinary care. No prior studies have characterized the sociodemographic characteristics across multiple VA centers. We collected data on 5783 patients receiving care at 20 VA centers between July 1, 2020 through December 31, 2022. Male patients were underrepresented compared to the state‐level census data at 17/20 centers. Black and Asian patients were underrepresented at 14/20 and 12/20 centers, respectively. The median distance to the hospital was 48 miles, and median age was 12.0 years. These data suggest that race, sex, age, and distance from the hospital could impede the ability to access expert VA care.
- Open Access
- 4 March 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (5) , e30921
How we use angiopoietin‐2 in the diagnosis and management of vascular anomalies
The diagnosis of vascular anomalies remains challenging due to significant clinical heterogeneity and uncertain etiology. Evaluation using biopsy and/or genetic testing for somatic variants is invasive, expensive, and prone to sampling error. There is great need for noninvasive and easily measured blood laboratory biomarkers that can aid not only in diagnosis, but also management of treatments for vascular anomalies. Angiopoietin‐2, a circulating blood angiogenic factor, is highly elevated in patients with kaposiform hemangioendothelioma with Kasabach–Merritt phenomenon and kaposiform lymphangiomatosis. Here, we describe our clinical experience using serum angiopoietin‐2 as a biomarker for diagnosis and monitoring response to treatment.
- 4 March 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (5) , e30921
Open AccessHow we use angiopoietin‐2 in the diagnosis and management of vascular anomalies
The diagnosis of vascular anomalies remains challenging due to significant clinical heterogeneity and uncertain etiology. Evaluation using biopsy and/or genetic testing for somatic variants is invasive, expensive, and prone to sampling error. There is great need for noninvasive and easily measured blood laboratory biomarkers that can aid not only in diagnosis, but also management of treatments for vascular anomalies. Angiopoietin‐2, a circulating blood angiogenic factor, is highly elevated in patients with kaposiform hemangioendothelioma with Kasabach–Merritt phenomenon and kaposiform lymphangiomatosis. Here, we describe our clinical experience using serum angiopoietin‐2 as a biomarker for diagnosis and monitoring response to treatment.
- 10 December 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30779
Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study
Background and objectives: Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA) are rare vascular tumors in children historically associated with significant morbidity and mortality. This study was conducted to determine first‐line therapy in the absence of available prospective clinical trials.Methods: Patients from 17 institutions diagnosed with KHE/TA between 2005 and 2020 with more than 6 months of follow‐up were included. Response rates to sirolimus and vincristine were compared at 3 and 6 months. Durability of response and response to other treatment modalities were also evaluated.Results: Of 159 unique KHE/TA subjects, Kasabach–Merritt phenomenon (KMP) was present in 64 (40.3%), and only two patients were deceased (1.3%). Over 60% (n = 96) demonstrated treatment response at 3 months, and more than 70% (n = 114) by 6 months (no significant difference across groups). The vincristine group had higher radiologic response at 3 months compared to sirolimus (72.7% vs. 20%, p = .03), but there were no differences between these groups at 6 months. There were no differences in rates of recurrent or progressive disease between vincristine and sirolimus.Conclusions: In this large, multicenter cohort of 159 patients with KHE/TA, rates of KMP were consistent with historical literature, but the mortality rate (1.3%) was much lower. Overall treatment response rates were high (>70%), and there was no significant difference in treatment response or durability of disease comparing sirolimus to vincristine. Our results support individualized treatment decision plans depending on clinical scenario and patient/physician preferences. Response criteria and response rates reported here will be useful for guiding future treatment protocols for vascular tumors.
- 10 December 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30779
Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study
Background and objectives: Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA) are rare vascular tumors in children historically associated with significant morbidity and mortality. This study was conducted to determine first‐line therapy in the absence of available prospective clinical trials.Methods: Patients from 17 institutions diagnosed with KHE/TA between 2005 and 2020 with more than 6 months of follow‐up were included. Response rates to sirolimus and vincristine were compared at 3 and 6 months. Durability of response and response to other treatment modalities were also evaluated.Results: Of 159 unique KHE/TA subjects, Kasabach–Merritt phenomenon (KMP) was present in 64 (40.3%), and only two patients were deceased (1.3%). Over 60% (n = 96) demonstrated treatment response at 3 months, and more than 70% (n = 114) by 6 months (no significant difference across groups). The vincristine group had higher radiologic response at 3 months compared to sirolimus (72.7% vs. 20%, p = .03), but there were no differences between these groups at 6 months. There were no differences in rates of recurrent or progressive disease between vincristine and sirolimus.Conclusions: In this large, multicenter cohort of 159 patients with KHE/TA, rates of KMP were consistent with historical literature, but the mortality rate (1.3%) was much lower. Overall treatment response rates were high (>70%), and there was no significant difference in treatment response or durability of disease comparing sirolimus to vincristine. Our results support individualized treatment decision plans depending on clinical scenario and patient/physician preferences. Response criteria and response rates reported here will be useful for guiding future treatment protocols for vascular tumors.
- 23 October 2023
- Published by Elsevier in Oral and Maxillofacial Surgery Clinics of North America
- Vol. 36 (1) , 103-113
Medical Management of Nonmalignant Vascular Tumors of the Head and Neck
- 23 October 2023
- Published by Elsevier in Oral and Maxillofacial Surgery Clinics of North America
- Vol. 36 (1) , 103-113
Medical Management of Nonmalignant Vascular Tumors of the Head and Neck
- 21 October 2023
- Published by Elsevier in Oral and Maxillofacial Surgery Clinics of North America
- Vol. 36 (1) , 125-136
Medical Therapeutics for the Treatment of Vascular Anomalies
- 21 October 2023
- Published by Elsevier in Oral and Maxillofacial Surgery Clinics of North America
- Vol. 36 (1) , 125-136
Medical Therapeutics for the Treatment of Vascular Anomalies
- Open Access
- 12 August 2023
- Published by Wiley
Treatment practices and response in Kaposiform hemangioendothelioma: a multi-center cohort study
Background and Objectives: Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA) are rare vascular tumors in children historically associated with significant morbidity and mortality. This study was conducted to determine first line therapy in the absence of available prospective clinical trials. Methods: Patients from 17 institutions diagnosed with KHE/TA between 2005-2020 with > 6 months follow-up were included. Response rates to sirolimus and vincristine were compared at 3 and 6 months. Durability of response and response to other treatment modalities were also evaluated. Results: Of 159 unique KHE/TA subjects, Kasabach-Merritt phenomenon (KMP) was present in 64 (40.3%) and only 2 patients were deceased (1.3%). Over 60% (n=96) demonstrated treatment response at 3 months and >70% (n=114) by 6 months (no significant difference across groups). The vincristine group had higher radiologic response at 3 months compared to sirolimus (72.7% vs 20%, p=0.03) but there was no differences between these groups at 6 months. There were no differences in rates of recurrent or progressive disease between vincristine and sirolimus. Conclusions: In this large, multicenter cohort of 159 patients with KHE/TA, rates of KMP were consistent with historical literature but the mortality rate (1.3%) was much lower. Overall treatment response rates were high (>70%) and there were no significant difference in treatment response or durability of disease comparing sirolimus to vincristine. Our results support individualized treatment decision plans depending on clinical scenario and patient/physician preferences. Response criteria and response rates reported here will be useful for guiding future treatment protocols for vascular tumors.
- 12 August 2023
- Published by Wiley
Open AccessTreatment practices and response in Kaposiform hemangioendothelioma: a multi-center cohort study
Background and Objectives: Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA) are rare vascular tumors in children historically associated with significant morbidity and mortality. This study was conducted to determine first line therapy in the absence of available prospective clinical trials. Methods: Patients from 17 institutions diagnosed with KHE/TA between 2005-2020 with > 6 months follow-up were included. Response rates to sirolimus and vincristine were compared at 3 and 6 months. Durability of response and response to other treatment modalities were also evaluated. Results: Of 159 unique KHE/TA subjects, Kasabach-Merritt phenomenon (KMP) was present in 64 (40.3%) and only 2 patients were deceased (1.3%). Over 60% (n=96) demonstrated treatment response at 3 months and >70% (n=114) by 6 months (no significant difference across groups). The vincristine group had higher radiologic response at 3 months compared to sirolimus (72.7% vs 20%, p=0.03) but there was no differences between these groups at 6 months. There were no differences in rates of recurrent or progressive disease between vincristine and sirolimus. Conclusions: In this large, multicenter cohort of 159 patients with KHE/TA, rates of KMP were consistent with historical literature but the mortality rate (1.3%) was much lower. Overall treatment response rates were high (>70%) and there were no significant difference in treatment response or durability of disease comparing sirolimus to vincristine. Our results support individualized treatment decision plans depending on clinical scenario and patient/physician preferences. Response criteria and response rates reported here will be useful for guiding future treatment protocols for vascular tumors.
- Open Access
- 18 January 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (4) , e30215
Response to sirolimus in capillary lymphatic venous malformations and associated syndromes: Impact on symptomatology, quality of life, and radiographic response
Background: Capillary lymphatic venous malformations (CLVM) and associated syndromes, including Klippel–Trenaunay syndrome (KTS) and congenital lipomatous overgrowth, vascular malformation, epidermal nevi, skeletal, and spinal syndrome (CLOVES), are underrecognized disorders associated with high morbidity from chronic pain, recurrent infections, bleeding, and clotting complications. The rarity of these disorders and heterogeneity of clinical presentations make large‐scale randomized clinical drug trials challenging. Identification of PIK3CA (phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha [gene]) mutations in CLVM has made targeted medications, such as sirolimus, attractive treatment options. The aim of this study was to investigate the safety and efficacy of sirolimus therapy in CLVM.Procedure: A combined prospective and retrospective cohort of pediatric and young adult patients with CLVM treated with sirolimus was evaluated for disease response, including symptom improvement, quality of life (QOL), and radiologic response. Sirolimus dosing regimens and toxicities were also assessed.Results: Twenty‐nine patients with CLVM, including KTS and CLOVES, were included. Ninety‐three percent of patients reported improved QOL, and 86% had improvement in at least one symptom. Most significantly, improvement was noted in 100% of patients with bleeding and 89% with thrombotic complications with corresponding decreases in mean D‐dimer (p = .008) and increases in mean fibrinogen (p = .016). No patients had progressive disease on sirolimus. Most common side effects included neutropenia, lymphopenia, infection, and aphthous ulcers/stomatitis. No toxicities were life‐threatening, and none required long‐term discontinuation of sirolimus.Conclusion: Sirolimus appears to be effective at reducing complications and improving QOL in patients with CLVM and associated syndromes. In this patient cohort, sirolimus was well tolerated and resulted in few treatment‐related toxicities.
- 18 January 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (4) , e30215
Open AccessResponse to sirolimus in capillary lymphatic venous malformations and associated syndromes: Impact on symptomatology, quality of life, and radiographic response
Background: Capillary lymphatic venous malformations (CLVM) and associated syndromes, including Klippel–Trenaunay syndrome (KTS) and congenital lipomatous overgrowth, vascular malformation, epidermal nevi, skeletal, and spinal syndrome (CLOVES), are underrecognized disorders associated with high morbidity from chronic pain, recurrent infections, bleeding, and clotting complications. The rarity of these disorders and heterogeneity of clinical presentations make large‐scale randomized clinical drug trials challenging. Identification of PIK3CA (phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha [gene]) mutations in CLVM has made targeted medications, such as sirolimus, attractive treatment options. The aim of this study was to investigate the safety and efficacy of sirolimus therapy in CLVM.Procedure: A combined prospective and retrospective cohort of pediatric and young adult patients with CLVM treated with sirolimus was evaluated for disease response, including symptom improvement, quality of life (QOL), and radiologic response. Sirolimus dosing regimens and toxicities were also assessed.Results: Twenty‐nine patients with CLVM, including KTS and CLOVES, were included. Ninety‐three percent of patients reported improved QOL, and 86% had improvement in at least one symptom. Most significantly, improvement was noted in 100% of patients with bleeding and 89% with thrombotic complications with corresponding decreases in mean D‐dimer (p = .008) and increases in mean fibrinogen (p = .016). No patients had progressive disease on sirolimus. Most common side effects included neutropenia, lymphopenia, infection, and aphthous ulcers/stomatitis. No toxicities were life‐threatening, and none required long‐term discontinuation of sirolimus.Conclusion: Sirolimus appears to be effective at reducing complications and improving QOL in patients with CLVM and associated syndromes. In this patient cohort, sirolimus was well tolerated and resulted in few treatment‐related toxicities.
- Open Access
- 8 September 2022
- Published by Wiley
Intra-abdominal Lymphatic Malformations: A Case Series
Background: Intra-abdominal lymphatic malformations are rare entities without a clear consensus on management or prognosis. These malformations are medically and surgically complex and often require a sophisticated, multi-disciplinary approach to treatment. Methods: A single quaternary institutional, retrospective chart review between January 2000-December 2019 was performed on all patients with an initial diagnosis of a non-solid organ intra-abdominal lymphatic malformation. Demographics, presentation, treatment, and outcome were reviewed. Results: 24 patients were identified, 62.5% were male. Median age at time of diagnosis was 2.5 years old, 33% were present at birth, 50% presented before 2 years old, and 29% presented ≥10 years of age. 75% were lymphatic (majority macrocystic), 20.8% were mixed lymphatic-venous malformations (LVM). 54% had other associated lymphatic or vascular malformations including 4 patients with PIK3CA-Related Overgrowth Spectrum (PROS), 3 with Generalized Lymphatic Anomaly, and 2 with Capillary Venous Lymphatic malformation (CVLM). Patients most often presented with abdominal pain (50%). 95.8% required an intervention. 87.5% were managed initially with sclerotherapy. Most interventions were performed for abdominal symptoms either before three years of age or during adolescence. 41.7% underwent laparoscopic or open surgery. 8.3% underwent surgery as their primary therapy. Conclusion: Intra-abdominal lymphatic malformations have a bimodal distribution pattern of presentation; shortly after birth and again at puberty. Most patients present with abdominal symptoms and have other associated vascular anomalies. MRI appears to be the most accurate modality for treatment planning. Interventional procedures such as sclerotherapy and medical therapy with sirolimus are safe and effective and should be considered first line therapies. Surgical resection is often required when the diagnosis is in question or when more conservative therapies are no longer efficacious.
- 8 September 2022
- Published by Wiley
Open AccessIntra-abdominal Lymphatic Malformations: A Case Series
Background: Intra-abdominal lymphatic malformations are rare entities without a clear consensus on management or prognosis. These malformations are medically and surgically complex and often require a sophisticated, multi-disciplinary approach to treatment. Methods: A single quaternary institutional, retrospective chart review between January 2000-December 2019 was performed on all patients with an initial diagnosis of a non-solid organ intra-abdominal lymphatic malformation. Demographics, presentation, treatment, and outcome were reviewed. Results: 24 patients were identified, 62.5% were male. Median age at time of diagnosis was 2.5 years old, 33% were present at birth, 50% presented before 2 years old, and 29% presented ≥10 years of age. 75% were lymphatic (majority macrocystic), 20.8% were mixed lymphatic-venous malformations (LVM). 54% had other associated lymphatic or vascular malformations including 4 patients with PIK3CA-Related Overgrowth Spectrum (PROS), 3 with Generalized Lymphatic Anomaly, and 2 with Capillary Venous Lymphatic malformation (CVLM). Patients most often presented with abdominal pain (50%). 95.8% required an intervention. 87.5% were managed initially with sclerotherapy. Most interventions were performed for abdominal symptoms either before three years of age or during adolescence. 41.7% underwent laparoscopic or open surgery. 8.3% underwent surgery as their primary therapy. Conclusion: Intra-abdominal lymphatic malformations have a bimodal distribution pattern of presentation; shortly after birth and again at puberty. Most patients present with abdominal symptoms and have other associated vascular anomalies. MRI appears to be the most accurate modality for treatment planning. Interventional procedures such as sclerotherapy and medical therapy with sirolimus are safe and effective and should be considered first line therapies. Surgical resection is often required when the diagnosis is in question or when more conservative therapies are no longer efficacious.
- 12 April 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (S3) , e28985
How we approach the diagnosis and management of complex lymphatic anomalies
Complex lymphatic anomalies (CLA) are congenital diseases of the lymphatic circulation system that are associated with significant morbidity and early mortality. While guidelines for the comprehensive evaluation of the CLA were recently published, the diagnostic approach and medical management are not standardized. This article presents the clinical features of four CLA: Gorham–Stout disease, generalized lymphatic anomaly, kaposiform lymphangiomatosis, and central collecting lymphatic anomaly. We also offer three cases from the authors’ practice and our views on diagnostic testing and disease management including supportive care, medical therapies, and other interventions.
- 12 April 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (S3) , e28985
How we approach the diagnosis and management of complex lymphatic anomalies
Complex lymphatic anomalies (CLA) are congenital diseases of the lymphatic circulation system that are associated with significant morbidity and early mortality. While guidelines for the comprehensive evaluation of the CLA were recently published, the diagnostic approach and medical management are not standardized. This article presents the clinical features of four CLA: Gorham–Stout disease, generalized lymphatic anomaly, kaposiform lymphangiomatosis, and central collecting lymphatic anomaly. We also offer three cases from the authors’ practice and our views on diagnostic testing and disease management including supportive care, medical therapies, and other interventions.